Clinical trials in Warsaw – page 108

1 804 clinical trials in Warsaw, Poland across 33 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PolandBadaniaKliniczne.pl

Warsaw at a glance

1 804

clinical trials

Research sites33

Quick filters

1 804 trials in Warsaw

Open in trial search

Gastric cancer+1

Not recruiting

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Jazz Pharmaceuticals Ireland Limited

Contact Research Centre

Study on Pembrolizumab and Eftilagimod Alfa with Radiotherapy for Patients with Resectable Soft Tissue Sarcomas

Not recruiting

Registered drugNo placebo

Study on Pembrolizumab and Eftilagimod Alfa with Radiotherapy for Patients with Resectable Soft Tissue Sarcomas

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Eftilagimod Alfa
Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy

Contact Research Centre

Desmoid tumour

Not recruiting

Study of varegacestat (AL102) in patients with progressing desmoid tumors

Investigational

Study of varegacestat (AL102) in patients with progressing desmoid tumors

Investigational

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Varegacestat
Sponsor:Immunome Inc.

Contact Research Centre

Oesophageal carcinoma

Not recruiting

Study of RO7121661, RO7247669, and Nivolumab for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo

Study of RO7121661, RO7247669, and Nivolumab for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Chronic fatigue syndrome+1

Not recruiting

Study of Pregabalin Treatment and Rehabilitation for Chronic Fatigue in Post-COVID Syndrome Patients

Registered drug

Study of Pregabalin Treatment and Rehabilitation for Chronic Fatigue in Post-COVID Syndrome Patients

Registered drug

Poland

Participants:18–64 years
Substances:Pregabalin
Sponsor:Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher

Contact Research Centre

Renal cell carcinoma

Not recruiting

Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment

Registered drugNo placebo

Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Crohn's disease

Not recruiting

Study on the Safety and Effectiveness of AZD7798 for Adults with Ileal Crohn's Disease and an Ileostomy

Investigational

Study on the Safety and Effectiveness of AZD7798 for Adults with Ileal Crohn's Disease and an Ileostomy

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Azd7798
Sponsor:AstraZeneca AB

Contact Research Centre

Triple negative breast cancer

Not recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Triple negative breast cancer

Not recruiting

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Hidradenitis

Not recruiting

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational

Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational

Poland

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lutikizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Fabry's disease

Not recruiting

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo

Study on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Lucerastat
Sponsor:Idorsia Pharmaceuticals Ltd.

Contact Research Centre

Myocarditis

Not recruiting

Study of prednisone and azathioprine treatment in patients with virus-negative myocarditis or inflammatory heart muscle disease with reduced heart pump function

Registered drug

Study of prednisone and azathioprine treatment in patients with virus-negative myocarditis or inflammatory heart muscle disease with reduced heart pump function

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Medical University Of Warsaw

Contact Research Centre

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Warsaw

What the registry says about research in the country

01 Respiratory Disease Research

Innovative trials focusing on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) prevention in older adults. Studies include evaluation of novel vaccine formulations and immune responses in various age groups.

RSV Prevention Studies
Influenza Vaccine Research
Respiratory Infection Management

Particular emphasis on vaccine development for adults aged 60 and older.

02 Immunology Studies

Comprehensive research on meningococcal vaccines across different age groups, from infants to toddlers. Studies evaluate safety profiles and immune responses to various vaccine formulations.

Pediatric Vaccine Development
Immunogenicity Assessment
Vaccine Safety Monitoring

Focus on preventive healthcare through advanced vaccination strategies.

03 Dermatology Research

Studies investigating treatments for psoriasis and psoriatic arthritis, including novel biological therapies and their mechanisms of action.

Plaque Psoriasis Treatment
Biomarker Analysis
Combined Therapy Approaches

Emphasis on moderate to severe cases requiring advanced therapeutic interventions.

04 Oncology Studies

Clinical research focusing on bladder cancer and innovative combination therapies. Studies evaluate treatment efficacy in early-stage non-muscle invasive cases.

Immunotherapy Research
Cancer Treatment Combinations
Disease-Free Survival Analysis

Integration of targeted therapies with standard treatments.

Back to Poland All countries